Egypt-based biotech startup, Reme-D, has secured $500,000 in fresh funding from the Global Innovation Fund (GIF) to accelerate the expansion of its groundbreaking molecular diagnostics solutions across Africa and the Middle East.
Founded in 2022 by Salma Tammam, the startup is pioneering a new generation of PCR testing kits that can function reliably at room temperature. This eliminates the long-standing dependence on cold-chain storage systems that often hinder medical testing in low-resource environments.
The investment is expected to strengthen Reme-D’s manufacturing capacity, deepen its research in critical disease areas such as oncology and genetic disorders, and support its planned expansion into new markets including Nigeria and Libya.
With its already expanding footprint across Egypt, Iraq, Sudan, and Kenya, the company’s innovation is increasingly being viewed as a practical response to one of healthcare’s most persistent infrastructural challenges in developing regions.
What is Reme-D and What It Does
Reme-D is a molecular diagnostics company focused on improving access to reliable medical testing in environments with limited infrastructure. The company develops PCR (Polymerase Chain Reaction) testing kits, which are widely used in detecting infections and diseases by identifying genetic material.
What makes Reme-D unique is that its testing kits are designed to remain stable at room temperature, removing the need for refrigeration or frozen storage. This innovation is especially important in many developing regions where hospitals and laboratories often struggle with inconsistent electricity supply and lack of cold storage systems.
By eliminating this requirement, Reme-D’s solution makes advanced diagnostics more practical, affordable, and widely accessible.
The company achieves this through the use of nanotechnology and lyophilisation techniques, which essentially preserve biological materials in a stable, freeze-dried state that can be activated when needed for testing.
Breakthrough in Molecular Diagnostics Technology
Reme-D’s innovation addresses one of the most critical challenges in global healthcare delivery: the cold-chain dependency of diagnostic tools. Traditionally, PCR reagents must be stored at low temperatures from production to deployment, requiring expensive logistics and reliable power infrastructure.
By eliminating this requirement, Reme-D reduces operational costs by up to 40%, significantly lowering the financial burden on healthcare systems. In addition, the technology minimizes reagent waste and improves test reliability, particularly in remote or under-resourced health facilities.
Another major advantage of the system is efficiency. In some applications, Reme-D’s solution has been reported to reduce testing time by as much as 70%, enabling faster diagnosis and quicker treatment decisions.
This is especially crucial in managing infectious diseases, where delays in diagnosis can lead to widespread transmission or worsened patient outcomes.
Operational Reach Across Africa and the Middle East
Reme-D has already built a growing presence across several countries, including Egypt, Iraq, Sudan, and Kenya, supporting healthcare delivery in 92 healthcare facilities.
The company currently tests approximately 50,000 patients monthly, reflecting both the scale of demand and the increasing reliance on its technology across diverse healthcare environments.
Its expansion across these regions demonstrates the adaptability of its solutions in different medical systems and infrastructural conditions.
This operational footprint highlights Reme-D’s growing role not only as a biotech innovator but also as a practical enabler of healthcare delivery in regions where traditional diagnostic systems often face logistical and financial limitations.
Expansion Plans and Future Research Direction
Looking ahead, Reme-D is positioning itself for broader regional influence by deepening its presence in underserved healthcare markets. The planned expansion into Nigeria and Libya is expected to significantly increase access to molecular diagnostics in West and North Africa.
Beyond geographical expansion, the company is also intensifying its research efforts in complex disease areas. Genetic disorders, cancer detection (oncology), and maternal health diagnostics have been identified as priority sectors due to their high disease burden and diagnostic gaps in many developing countries.
These focus areas indicate a strategic shift from not only providing diagnostic tools but also contributing to long-term improvements in public health outcomes through targeted innovation.
Broader Significance for Healthcare Innovation in Emerging Markets
Reme-D’s approach reflects a broader transformation in global health innovation, one that prioritizes locally relevant, infrastructure-aware solutions over traditional imported technologies that may not suit developing environments.
By designing diagnostic tools that work without cold-chain dependency, the company is directly addressing one of the most persistent barriers to healthcare access in low-resource settings.
This positions Reme-D as part of a new generation of African and Middle Eastern health-tech companies redefining how medical technology is developed, deployed, and scaled.
Ultimately, the startup’s progress underscores a critical shift, that’s, innovation in healthcare is increasingly being shaped not just by scientific advancement, but by contextual understanding of where and how that science is applied.
_______________________
Bookmark Techparley.com for the most insightful technology news from the African continent.
Follow us on X/Twitter @Techparleynews, on Facebook at Techparley Africa, on LinkedIn at Techparley Africa, or on Instagram at Techparleynews
